Efficacy and safety of anagliptin add to insulin therapy in Japanese Patients with type 2 diabetes-a multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an open-label, long-term extension-
|
-
1
-
-
44949134945
-
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemie control?
-
Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemie control? Eur J Endocrinol 2008; 158 (6): 773-84.
-
(2008)
Eur J Endocrinol
, vol.158
, Issue.6
, pp. 773-784
-
-
Van Gaal, L.F.1
Gutkin, S.W.2
Nauck, M.A.3
-
2
-
-
0037241085
-
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
-
Vilsbøll T, Agersø H, Kramp T, Hoist JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88 (1): 220-4.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, Issue.1
, pp. 220-224
-
-
Vilsbøll, T.1
Agersø, H.2
Kramp, T.3
Hoist, J.J.4
-
3
-
-
77950880269
-
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
-
Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20 (4): 224-35.
-
(2010)
Nutr Metab Cardiovasc Dis
, vol.20
, Issue.4
, pp. 224-235
-
-
Monami, M.1
Iacomelli, I.2
Marchionni, N.3
Mannucci, E.4
-
4
-
-
44949134945
-
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: Glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemie control?
-
Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemie control? Eur J Endocrinol 2008; 158: 773-84.
-
(2008)
Eur J Endocrinol
, vol.158
, pp. 773-784
-
-
Van Gaal, L.F.1
Gutkin, S.W.2
Nauck, M.A.3
-
5
-
-
0025066579
-
Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM
-
Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39 (11): 1381-90.
-
(1990)
Diabetes
, vol.39
, Issue.11
, pp. 1381-1390
-
-
Mitrakou, A.1
Kelley, D.2
Veneman, T.3
Jenssen, T.4
Pangburn, T.5
-
6
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS)Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53.
-
(1998)
Lancet
, vol.352
, Issue.9131
, pp. 837-853
-
-
UK Prospective Diabetes Study (UKPDS) Group1
-
7
-
-
0035847591
-
Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria
-
DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
-
(2001)
Arch Intern Med
, vol.161
, pp. 397-405
-
-
|